Pharmacokinetics News and Research

RSS

The term pharmacokinetics is derived from the ancient Greek words “pharmakon” and “kinetikos”, meaning “drug” and “putting in motion” respectively. It is one of the main branches of pharmacology, and refers to the way that the body reacts on and affects a pharmaceutical substance in the body.

ImmunoGen announces FDA approval of IMGN289 Investigational New Drug

ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops novel anticancer therapeutics using its Targeted Antibody Payload (TAP) ADC technology, today announced that the Company's x (IND) application has been accepted by the US FDA and is now active.

2 Aug 2013

NOXXON completes patient recruitment of NOX-E36 Phase IIa trial for treatment of diabetic nephropathy

NOXXON Pharma today announced the successful completion of patient recruitment of its NOX-E36 Phase IIa clinical trial for the treatment of diabetic nephropathy. NOX-E36 is a Spiegelmer® that binds and neutralizes CCL2/MCP-1 (C-C Chemokine Ligand / Monocyte Chemoattractant Protein-1), a pro-inflammatory chemokine that plays an important role in the progression of diabetic nephropathy, the most common single cause of chronic kidney failure and end-stage renal disease.

25 Jul 2013

Child cancer survival: an interview with Prof Kathy Pritchard-Jones, University College London

Back in the early 1960s, just before chemotherapy really started to be used, only about 30% of children survived cancer. That was mainly because they had cancers that were amenable to surgery.

24 Jul 2013

Bacillus-derived Hyaluronic acid from Novozymes Biopharma, Hyasis®, increases in vitro drug release time from under 10 minutes to approximately 15 hours

An investigation undertaken by Novozymes Biopharma DK has shown that when the corticosteroid dexamethasone is formulated in a cross-linked Hyaluronic acid (HA) hydrogel, the drug’s in vitro release time increases from under 10 minutes to approximately 15 hours. In addition, the in vivo half-life of dexamethasone is shown to plateau with stable dexamethasone concentration up to four hours after injection.

22 Jul 2013

Human filariasis research: an interview with Professor Mark Taylor, Liverpool School of Tropical Medicine

Filariasis refers to a group of diseases caused by parasitic worms, which are transmitted by blood feeding insects. Two species infect the lymphatic and blood systems causing lymphatic filariasis, which in some people can lead to gross swelling of the limbs and 'elephantiasis'.

18 Jul 2013

Spectrum Pharmaceuticals enters into agreement to acquire Talon Therapeutics

Spectrum Pharmaceuticals, Inc., a biotechnology company with fully-integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced that, through a wholly-owned subsidiary, the company entered into an agreement to acquire Talon Therapeutics, Inc., a biopharmaceutical company based in South San Francisco, California, and expects to complete the acquisition within one day.

17 Jul 2013

Scientists develop statistical models to predict which drug is best for specific disease

Medicines that are personally tailored to your DNA are becoming a reality, thanks to the work of U.S. and Chinese scientists who developed statistical models to predict which drug is best for a specific individual with a specific disease.

17 Jul 2013

Bayer starts enrollment in BAY94-9027 Phase II/III trial for hemophilia A in children

Bayer HealthCare today announced the company has started to enroll patients in an international Phase II/III trial to evaluate its investigational compound BAY94-9027 for the treatment of hemophilia A in children.

8 Jul 2013

Probiodrug to present studies on PQ912 for treatment of Alzheimer's disease at AAIC meeting

Probiodrug AG (Probiodrug) announced that it will be making two poster and two oral presentations at the upcoming Alzheimer's Association International Conference in Boston, MA July 13 - 18, 2013.

8 Jul 2013

Biogen, Sobi present new data supporting clinical, safety profile of ELOCTATE for hemophilia A

Biogen Idec nd Swedish Orphan Biovitrum AB (publ) presented new data that support the clinical and safety profile of their long-lasting recombinant factor VIII candidate ELOCTATE for hemophilia A.

4 Jul 2013

CTI announces publication of preclinical, clinical data for pacritinib in Drugs of the Future 2013

Cell Therapeutics, Inc. today announced that a comprehensive article summarizing preclinical and clinical data for pacritinib, an oral JAK2/FLT3 inhibitor, authored by Srdan Verstovsek, M.D., Ph.D., et al., was published in the journal Drugs of the Future 2013.

3 Jul 2013

Biogen, Sobi present new findings from Phase 3 trial of ALPROLIX at XXIV ISTH Congress

Biogen Idec and Swedish Orphan Biovitrum AB (publ) today presented new findings for their long-lasting recombinant factor IX candidate ALPROLIX for hemophilia B at the XXIV International Society on Thrombosis and Haemostasis Congress in Amsterdam, The Netherlands.

3 Jul 2013

Idera Pharmaceuticals reports Phase 1 clinical trial results of IMO-8400

Idera Pharmaceuticals, Inc. announced results of a Phase 1 clinical trial of IMO-8400, a first-in-class antagonist of Toll-like Receptors 7, 8, and 9 being developed for potential applications in autoimmune and inflammatory diseases.

2 Jul 2013

Bayer, Onyx submit sNDA to FDA, marketing authorization application to EMA for Nexavar tablets

Bayer HealthCare and Onyx Pharmaceuticals today announced the submission of a supplemental New Drug Application to the U.S. Food and Drug Administration and an application for marketing authorization to the European Medicines Agency for the oral multi-kinase inhibitor Nexavar (sorafenib) tablets for the treatment of locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer.

1 Jul 2013

FX006 demonstrates pain relief in Phase 2b osteoarthritis study, Flexion reports

Flexion Therapeutics, Inc., today reported that its lead compound FX006, a novel intra-articular, sustained release steroid, demonstrated pain relief that is of both greater magnitude and longer duration than the most commonly prescribed immediate release steroid, triamcinolone acetonide, in a Phase 2b dose-ranging trial in osteoarthritis.

27 Jun 2013

Researchers say hCNT1 protein may affect cancer cells physiology, apart from transport function

The protein hCNT1, which plays a major role in nucleoside transport, may have other biological functions that may affect cancer cells physiology, apart from their transport function. This is the main conclusion of the new scientific work published on the journal Cell Death and Disease.

26 Jun 2013

Verastem announces initiation of VS-4718 Phase 1 trial in patients with advanced cancer

Verastem, Inc., focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, announced the initiation of a Phase 1 trial of VS-4718, a novel, small molecule inhibitor of focal adhesion kinase, in patients with advanced cancer.

26 Jun 2013

Controlled drug release using novel excipients: an interview with Dr Laura Waters, University of Huddersfield

When you take a medicine you may want the drug to all be released immediately or perhaps more slowly over a longer period of time. If we can make a medicine where we control the release then we can tailor our medicines to release at the exact rate we choose that is best for the patient.

26 Jun 2013

Sarah Cannon Research Institute opens enrollment in Phase I clinical study with MORAb-066

Morphotek, Inc., a subsidiary of Eisai Inc., announced today that the Sarah Cannon Research Institute in Nashville, Tennessee has opened enrollment in a Phase I clinical study with MORAb-066 in patients with advanced or metastatic breast, pancreatic, colorectal or non-small cell lung cancer (adenocarcinoma) malignancies.

26 Jun 2013

AtheroNova starts AHRO-001 Phase 1 clinical trial for treatment of atherosclerosis

AtheroNova Inc., a biotech company focused on the research and development of compounds to safely regress atherosclerotic plaque and improve lipid profiles in humans, today announces achievement of a major milestone with the initiation of a Phase 1 clinical trial with its lead compound, AHRO-001. The Phase 1 study will evaluate the safety, tolerability and pharmacokinetics of AHRO-001 in healthy volunteers.

25 Jun 2013

Pharmacokinetics News and Research

Further Reading

ImmunoGen announces FDA approval of IMGN289 Investigational New Drug

NOXXON completes patient recruitment of NOX-E36 Phase IIa trial for treatment of diabetic nephropathy

Child cancer survival: an interview with Prof Kathy Pritchard-Jones, University College London

Bacillus-derived Hyaluronic acid from Novozymes Biopharma, Hyasis®, increases in vitro drug release time from under 10 minutes to approximately 15 hours

Human filariasis research: an interview with Professor Mark Taylor, Liverpool School of Tropical Medicine

Spectrum Pharmaceuticals enters into agreement to acquire Talon Therapeutics

Scientists develop statistical models to predict which drug is best for specific disease

Bayer starts enrollment in BAY94-9027 Phase II/III trial for hemophilia A in children

Probiodrug to present studies on PQ912 for treatment of Alzheimer's disease at AAIC meeting

Biogen, Sobi present new data supporting clinical, safety profile of ELOCTATE for hemophilia A

CTI announces publication of preclinical, clinical data for pacritinib in Drugs of the Future 2013

Biogen, Sobi present new findings from Phase 3 trial of ALPROLIX at XXIV ISTH Congress

Idera Pharmaceuticals reports Phase 1 clinical trial results of IMO-8400

Bayer, Onyx submit sNDA to FDA, marketing authorization application to EMA for Nexavar tablets

FX006 demonstrates pain relief in Phase 2b osteoarthritis study, Flexion reports

Researchers say hCNT1 protein may affect cancer cells physiology, apart from transport function

Verastem announces initiation of VS-4718 Phase 1 trial in patients with advanced cancer

Controlled drug release using novel excipients: an interview with Dr Laura Waters, University of Huddersfield

Sarah Cannon Research Institute opens enrollment in Phase I clinical study with MORAb-066

AtheroNova starts AHRO-001 Phase 1 clinical trial for treatment of atherosclerosis

Industry Focus - Biopharma eBook

How can microdialysis benefit drug development

Global and Local Efforts to Take Action Against Hepatitis

Addressing Important Cardiac Biology Questions with Shotgun Top-Down Proteomics

Latest News